Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

First-generation epidermal growth factor receptor (EGFR) targeted kinase inhibitors (TKIs) are still used in selected non-small cell lung cancer (NSCLC) patients despite the resistance. Based on the correlation of programmed cell death receptor ligand 1 (PD-L1) and EGFR signaling pathway, whether co...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Li, Guo, Fuchun, Liu, Xiaoke, Li, Xiaoyu, Qin, Qing, Shu, Pei, Li, Yi, Wang, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403384/
https://www.ncbi.nlm.nih.gov/pubmed/30842489
http://dx.doi.org/10.1038/s41598-018-38068-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403384/
https://www.ncbi.nlm.nih.gov/pubmed/30842489
http://dx.doi.org/10.1038/s41598-018-38068-3

Ejemplares similares